Welcome to our dedicated page for Amrize SEC filings (Ticker: AMRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amrize Ltd (NYSE: AMRZ) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. As a Switzerland-incorporated issuer listed on the New York Stock Exchange and the SIX Swiss Exchange, Amrize files reports with the U.S. Securities and Exchange Commission that give investors structured information about its operations and financial condition.
Recent Form 8-K filings from Amrize have reported quarterly financial results and related investor materials. These filings typically reference earnings press releases and investor presentations that discuss revenue by segment, non-GAAP metrics such as Adjusted EBITDA, Free Cash Flow, Net Debt and Net Leverage Ratio, and commentary on the performance of the Building Materials and Building Envelope segments. They also confirm details such as the company’s jurisdiction of incorporation in Switzerland and its principal executive office location in Zug.
On this page, investors can monitor new 8-K filings as they are released, along with other SEC forms when available, such as annual and quarterly reports that provide more comprehensive detail on Amrize’s business, risk factors and segment information. Filings related to capital structure, such as debt issuance, and any documents reporting significant events or transactions, are also part of the regulatory record.
Stock Titan enhances these filings with AI-powered summaries designed to explain the main points of lengthy documents in clear language. This can help readers quickly understand key topics such as segment performance, changes in leverage, major investments, or strategic initiatives like the ASPIRE program, while still allowing direct access to the full original filings for detailed analysis.
Amrize Ltd director Nicholas C. Gangestad reported routine equity compensation activity. He received a grant of 2,976 Ordinary Shares as a restricted stock unit award under the Amrize Ltd 2025 Omnibus Incentive Plan. The award vests on the earlier of the one-year anniversary of the grant date and the company’s next regular annual shareholder meeting.
On the same date, 740 Ordinary Shares were disposed of as a tax-withholding transaction at a reference price of $57.12 per share, covering tax obligations tied to the vesting. Following these transactions, Gangestad directly owns 4,218 Ordinary Shares.
Amrize Ltd director Gibson Dwight Audley Konrad reported routine equity compensation activity. He acquired 2,976 Ordinary Shares at no cost as a restricted stock unit award under the Amrize Ltd 2025 Omnibus Incentive Plan.
In connection with the vesting, 740 shares were disposed of to cover tax obligations at a price of $57.12 per share, a tax-withholding mechanism rather than an open-market sale. Following these transactions, he holds 2,218 Ordinary Shares directly.
Amrize Ltd director Wilbur Maria Cristina Alapag received a share-based compensation award. On April 21, 2026, Alapag acquired 2,976 Ordinary Shares at $0.00 per share as part of a restricted stock unit (RSU) award under the Amrize Ltd 2025 Omnibus Incentive Plan.
The filing also reports a related tax-withholding disposition of 190 Ordinary Shares at $57.12 per share, used to cover tax obligations on the vesting. Following these transactions, Alapag directly holds 2,958 Ordinary Shares.
Amrize Ltd director Sanche Jacques Wolf received an equity award of 2,976 Ordinary Shares as a restricted stock unit grant. The award was made at a price of $0.0000 per share under the Amrize Ltd 2025 Omnibus Incentive Plan and is described as a grant, award, or other acquisition.
The restricted stock units vest on the earlier of the one-year anniversary of the grant date and the date of Amrize Ltd's next regular annual meeting of shareholders. Following this grant, Wolf holds 5,616 Ordinary Shares directly and an additional 40 Ordinary Shares indirectly through a child.
Amrize Ltd director Robert S. Rivkin reported a share-based compensation event involving company ordinary shares. He received a grant of 2,976 shares at no cash cost as part of a restricted stock unit award under the Amrize Ltd 2025 Omnibus Incentive Plan.
In connection with the vesting of these restricted stock units, 740 shares were disposed of at a price of $57.12 per share to cover tax obligations, based on the closing price on the trading date of vesting. Following these transactions, his directly held ordinary shares were reported at 2,218.
Amrize Ltd director Roth Pellanda Katja Nicole reported compensation-related share activity. She acquired 2,976 Ordinary Shares at no cost as part of a restricted stock unit award under the Amrize Ltd 2025 Omnibus Incentive Plan. In a separate transaction, 190 Ordinary Shares were disposed of to cover tax obligations at a price of $57.12 per share.
The filing shows 5,744 Ordinary Shares held directly after the award transaction and 2,768 Ordinary Shares held directly after the tax-withholding disposition. The award vests on the earlier of the one-year anniversary of the grant date and the date of Amrize Ltd's next regular annual meeting of shareholders.
Amrize Ltd director Oleas Jurg Amadeo received a stock award and had shares withheld for taxes. On the reported date, he acquired 2,976 Ordinary Shares at no cost through a grant of restricted stock units under the Amrize Ltd 2025 Omnibus Incentive Plan. In a related tax-withholding disposition, 157 Ordinary Shares were delivered at a price of $57.12 per share to cover tax obligations on the vesting. After these transactions, he directly owns 20,916 Ordinary Shares.
NEWMAN DONALD P reported acquisition or exercise transactions in this Form 4 filing.
Amrize Ltd director Donald P. Newman received a restricted stock unit award of 2,976 Ordinary Shares. The grant was made at a price of $0.00 per share as equity compensation, increasing his direct holdings to 2,976 shares.
The award was granted under the Amrize Ltd 2025 Omnibus Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date and the date of the company’s next regular annual meeting of shareholders. This is a compensation-related equity grant rather than an open-market share purchase.
Amrize Ltd director Michael E. McKelvy reported equity compensation activity involving the company’s ordinary shares. He received 2,976 shares as a grant or award at a stated price of $0.00 per share, tied to a restricted stock unit award under the Amrize Ltd 2025 Omnibus Incentive Plan.
In a related tax-withholding disposition, 740 shares were delivered at $57.12 per share to cover tax obligations upon vesting. Following the tax-withholding transaction, the filing shows McKelvy directly holding 2,218 ordinary shares. The restricted stock units vest on the earlier of one year from grant or the issuer’s next regular annual meeting of shareholders.
Amrize Ltd director Ladhani Holli C. reported equity compensation activity involving Ordinary Shares. The filing shows a grant of 2,976 shares at no cost as a restricted stock unit award under the Amrize Ltd 2025 Omnibus Incentive Plan, which vests on the earlier of the one-year anniversary of the grant date or the issuer's next regular annual meeting of shareholders.
In a related tax-withholding disposition, 740 shares were delivered at a reference price of $57.12 per share, described as the closing price on the vesting date. One line in the filing shows 5,194 shares owned directly following the grant, while another shows 2,218 shares directly owned following the tax-withholding transaction, indicating routine compensation and tax-settlement activity rather than an open-market trade.